Delcath Systems 将来の成長

Future 基準チェック /56

Delcath Systemsは、70.4%と41.5%でそれぞれ年率70.4%で利益と収益が成長すると予測される一方、EPSはgrowで73.1%年率。

主要情報

70.4%

収益成長率

73.1%

EPS成長率

Medical Equipment 収益成長	14.8%
収益成長率	41.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	18 Oct 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BST:DV3R - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	134	34	45	45	6
12/31/2025	73	-5	12	14	6
12/31/2024	34	-37	-15	-19	6
6/30/2024	12	-56	-32	-31	N/A
3/31/2024	5	-50	-37	-37	N/A
12/31/2023	2	-48	-31	-31	N/A
9/30/2023	2	-45	-30	-30	N/A
6/30/2023	3	-34	-27	-26	N/A
3/31/2023	3	-37	-23	-23	N/A
12/31/2022	3	-37	-25	-25	N/A
9/30/2022	4	-33	-24	-24	N/A
6/30/2022	4	-32	-24	-23	N/A
3/31/2022	4	-28	-25	-24	N/A
12/31/2021	4	-26	-23	-23	N/A
9/30/2021	2	-27	-22	-22	N/A
6/30/2021	2	-25	-22	-21	N/A
3/31/2021	2	-23	-23	-22	N/A
12/31/2020	2	-24	-24	-23	N/A
9/30/2020	2	-5	-24	-23	N/A
6/30/2020	2	-7	-31	-31	N/A
3/31/2020	2	-9	-26	-26	N/A
12/31/2019	2	-9	-24	-24	N/A
9/30/2019	2	-32	-20	-20	N/A
6/30/2019	3	-34	-11	-11	N/A
3/31/2019	3	-34	-11	-11	N/A
12/31/2018	3	-19	-15	-15	N/A
9/30/2018	3	-28	-17	-17	N/A
6/30/2018	3	-32	-17	-17	N/A
3/31/2018	3	-27	N/A	-18	N/A
12/31/2017	3	-46	N/A	-15	N/A
9/30/2017	3	-34	N/A	-15	N/A
6/30/2017	2	-23	N/A	-15	N/A
3/31/2017	2	-27	N/A	-14	N/A
12/31/2016	2	-18	N/A	-14	N/A
9/30/2016	2	-15	N/A	-15	N/A
6/30/2016	2	-16	N/A	-14	N/A
3/31/2016	2	-13	N/A	-16	N/A
12/31/2015	2	-15	N/A	-16	N/A
9/30/2015	2	-13	N/A	-15	N/A
6/30/2015	1	-15	N/A	-16	N/A
3/31/2015	1	-16	N/A	-15	N/A
12/31/2014	1	-17	N/A	-16	N/A
9/30/2014	1	-19	N/A	-18	N/A
6/30/2014	1	-22	N/A	-21	N/A
3/31/2014	1	-23	N/A	-28	N/A
12/31/2013	1	-30	N/A	-34	N/A

アナリストによる今後の成長予測

収入対貯蓄率: DV3Rは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 1% ) よりも高い成長率であると考えられます。

収益対市場: DV3R今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: DV3R今後 3 年以内に収益を上げることが予想されます。

収益対市場: DV3Rの収益 ( 41.5% ) German市場 ( 5.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: DV3Rの収益 ( 41.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DV3Rの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Delcath Systems 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Forecast breakeven date moved forward to 2025

No longer forecast to breakeven

Delcath Systems, Inc. Provides Preliminary Earnings Guidance for the First Quarter Ended March 31, 2023

Forecast to breakeven in 2025

Recent updates

Forecast breakeven date moved forward to 2025

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Second quarter 2024 earnings released: US$0.48 loss per share (vs US$0.58 loss in 2Q 2023)

Delcath Systems Regains Compliance with the Audit Committee Composition Requirements

Delcath Systems, Inc. Appoints Bridget Martell to Board of Directors

New major risk - Financial position

New minor risk - Financial position

Delcath Systems, Inc. to Report Q1, 2024 Results on May 14, 2024

Delcath Systems, Inc Announces Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings released: US$2.94 loss per share (vs US$4.12 loss in FY 2022)

Delcath Systems, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

Delcath Systems, Inc. Announces Executive Changes

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit™

No longer forecast to breakeven

CEO & Director recently bought €93k worth of stock

Chief Medical Officer recently bought €137k worth of stock

Third quarter 2023 earnings released: US$1.14 loss per share (vs US$0.92 loss in 3Q 2022)

Insufficient new directors

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.58 loss per share (vs US$1.18 loss in 2Q 2022)

Delcath Systems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

Delcath Systems, Inc. Appoints Sandra Pennell as Senior Vice President of Finance

Delcath Systems, Inc. Provides Preliminary Earnings Guidance for the First Quarter Ended March 31, 2023

Full year 2022 earnings released: US$4.12 loss per share (vs US$3.59 loss in FY 2021)

Delcath Systems, Inc. Announces Board Changes

Delcath Systems, Inc. Announces New Drug Application Resubmission for HEPZATO Kit

Delcath Systems Announces Updated Results from Chopin Phase 1B Trial Published in Cardiovascular and Interventional Radiology

Forecast to breakeven in 2025

Independent Director recently bought €52k worth of stock

Delcath Systems, Inc. announced that it has received $6.201779 million in funding

Delcath Systems, Inc. Announces Results of Single Center Study on Delcath's CHEMOSAT Hepatic Delivery System in the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

Third quarter 2022 earnings released: US$0.92 loss per share (vs US$0.94 loss in 3Q 2021)

Delcath Systems, Inc. Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$1.18 loss per share (vs US$0.96 loss in 2Q 2021)

Results of A Multicenter Study on Delcath's Chemosat Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

Delcath Systems, Inc. announced that it has received $4.999998 million in funding

CEO & Director recently bought €245k worth of stock

Delcath Systems, Inc. announced that it expects to receive $5.000038 million in funding

First quarter 2022 earnings released: US$1.00 loss per share (vs US$1.04 loss in 1Q 2021)

High number of new and inexperienced directors

Delcath Systems, Inc., Annual General Meeting, May 04, 2022

Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT

Delcath Systems, Inc. Appoints Anthony Dias as its New Vice President of Finance

Delcath Systems, Inc. Announces Result of Single Center Study on Delcath’s CHEMOSAT Hepatic Delivery System Published in Melanoma Research

CEO & Director recently bought €177k worth of stock

Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$1.16 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.96 loss per share (vs US$1.91 loss in 2Q 2020)

Delcath Systems, Inc. announced that it expects to receive $20 million in funding from Avenue Capital Group

CEO & Director recently bought €125k worth of stock

Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$1.04 loss per share (vs US$108 loss in 1Q 2020)

Full year 2020 earnings released: US$8.36 loss per share (vs US$343 loss in FY 2019)

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘